We also need to understand mechanisms for resistance to trastuzumab deruxtecan as a single agent so we can develop combination therapies to further improve outcomes in this setting.” Trastuzumab ...

Trastuzumab deruxtecan-THP was associated with a statistically significant and clinically meaningful improvement in pathologic complete response rate vs standard of care. The DESTINY-Breast11 ...

Another possible mechanism of action is the preferential exertion of antibody- dependent cellular cytotoxicity on HER2-overexpressing cancer cells. [62] Trastuzumab contains an immunoglobulin G1 ...

With a median progression-free survival of more than three years, the DESTINY-Breast09 results show trastuzumab deruxtecan combined with pertuzumab has the potential to become a new first-line ...

October 01, 2024--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU ® (fam-trastuzumab deruxtecan ... the FDA action date for ...

The antibody-drug conjugate trastuzumab deruxtecan is approved for various therapeutic indications. Since March 2023, it can also be used as monotherapy for the treatment of adults with ...

Patients treated with trastuzumab deruxtecan + pertuzumab had a statistically significant and clinically meaningful improvement in PFS compared with standard of care. Topline results were ...

WILMINGTON, Del., May 07, 2025--(BUSINESS WIRE)--Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel ...

--(BUSINESS WIRE)-- Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically significant ...

With a median progression-free survival of more than three years, the DESTINY-Breast09 results show trastuzumab deruxtecan combined with pertuzumab has the potential to become a new first-line ...